Matsunaga, Akira

Compound Heterozygotes for a Novel Mutation, Apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with Severe Type III Hyperlipoproteinemia and Familial Hypercholesterolemia

Sakuma, N., Hibino, T., Saeki, T., Nagata, T., Sato, T., Okuda, N., Matsunaga, A., & Sasaki, J. (2014) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 6

Lipoprotein glomerulopathy with a novel apolipoprotein E variant, APOE Kanto (Asp 151dup)

Yokochi, A., Matsunaga, A., Kanemoto, K., Tominaga, N., Uda, S., & Saito, T. (2024) · CEN Case Reports

Renal Diseases and GlomerulopathiesLipid metabolism and disorders

Cited by 3

Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the academie study

ACADEMIE Study Investigators, Imaizumi, S., Shiga, Y., Ogawa, M., Sako, H., Nagata, Y., Matsunaga, A., Shirotani, T., Hoshino, F., Yahiro, E., et al. (2019) · Heart and Vessels

Blood Pressure and Hypertension StudiesHeart rate and cardiovascular health

Cited by 3